---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-25-000055"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:11:05.281733+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pacira Biosciences authorizes $300M share repurchase program through Dec 31, 2026

## Summary
- Board approved $300M stock buyback, effective immediately, replacing the May 7, 2024 program.
- Repurchases may be made on open market or via privately negotiated transactions at management's discretion.
- Program expires December 31, 2026; can be suspended or discontinued at any time by the company.
- No obligation to repurchase any specific number of shares under the authorization.

## SEC filing metadata
- accession: 0001396814-25-000055
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000055/0001396814-25-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000055/pcrx-20250417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-25-000055
- JSON: https://secwatch.observer/filing/0001396814-25-000055.json
- Plain text: https://secwatch.observer/filing/0001396814-25-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.